This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?

Capricor Therapeutics' EVP and General Counsel Karen Krasney sold 24,100 shares for ~$732,000 in June 2026 through a pre-planned 10b5-1 trading arrangement, which is routine stock-based compensation and not indicative of insider concerns. The stock has declined 30% year-to-date after a 202% surge in 2025. An FDA decision on Deramiocel approval is expected by August 22, 2026, which could serve as a significant catalyst for the clinical-stage biotech company.